Tutti gli studi
ReclutamentoConferma terapeutica (Fase III)Interventistico

An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura

This study is investigating a new approach to treating a rare and serious blood condition called immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP). Currently, a common treatment for iTTP is therapeutic plasma exchange (TPE), which involves filtering the patient's blood. This study aims to see if a medication called Cablivi, when given alongside standard immune-suppressing treatments, can help adult patients with iTTP go into remission and recover without needing TPE. Researchers will be closely monitoring how well patients respond to the treatment and if there are any side effects. This is a Phase III study, meaning it's a later stage of research designed to confirm if the new treatment is effective and safe.

A colpo d'occhio

Stato
Reclutamento
Fase
Conferma terapeutica (Fase III)
Sponsor
Sanofi-Aventis Ricerca & Sviluppo
Obiettivo di iscrizione
44
Inizio
11 Jul 2024

Di cosa tratta questo studio?

This study is about finding a new way to treat a rare but serious blood disease called immune-mediated Thrombotic Thrombocytopenic Purpura, or iTTP for short. In iTTP, your body mistakenly attacks itself, leading to tiny blood clots forming in small blood vessels. This can cause problems with your blood, kidneys, brain, and heart.

Currently, a common treatment for iTTP is called therapeutic plasma exchange, often shortened to TPE. This is a procedure where a machine filters your blood to remove harmful substances. While TPE is effective, it can be quite intensive and involves frequent hospital visits. This study is exploring if a new medicine called Cablivi, given along with other medicines that calm down your immune system, can help adult patients with iTTP get better and go into remission without needing the TPE procedure.

The main goal of the study is to see how many patients get better and into remission without needing TPE. The researchers will also be carefully watching for any side effects and how quickly people respond to the new treatment. This is an important step in potentially offering patients with iTTP a different, possibly less intensive, treatment option in the future.

Punti chiave

  • Tests a new medicine (Cablivi) for iTTP.
  • Aims to help patients get better without plasma exchange.
  • Combines Cablivi with other immune-suppressing treatments.
  • Involves regular hospital visits and monitoring.
  • Open to adults 18 years and older with iTTP.
  • Puoi smettere di partecipare in qualsiasi momento.

Chi può essere idoneo?

To join this study, you must be an adult, 18 years or older, and have been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP).

The study is open to both men and women with iTTP. There will be other specific medical checks to make sure the treatment is safe for you and that the study results are clear. These will involve looking at your overall health and any other medications you might be taking.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Have you been diagnosed with immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)?
  3. Are you able to attend regular hospital appointments for check-ups and treatment?
  4. Are you generally well enough to participate in a medical study in addition to your iTTP diagnosis?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you would receive the study medication, Cablivi, as an injection, along with other treatments to suppress your immune system. You would have regular appointments at the hospital or clinic for check-ups, blood tests, and to make sure the treatment is working well and safely. The study would involve close monitoring, especially in the beginning. The main part of the treatment will last for about 84 days (around 12 weeks), but you would be followed up for a longer period, up to 168 days (about 24 weeks), to see how you are doing after treatment.

Rischi e benefici potenziali

Participating in this study might offer the benefit of receiving a new treatment that could help you recover from iTTP without needing plasma exchange, potentially making your treatment journey less intensive. However, like all medicines, Cablivi can have side effects, and some might be serious. The study team will carefully monitor you for any problems. You are always in control of your decision; you can choose to join, and you can stop participating at any time, for any reason, without it affecting your usual medical care.

Luoghi (9)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Paesi Bassi
  • —
    Non verificato
    Repubblica Ceca
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Austria
  • —
    Non verificato
    Italia
  • —
    Non verificato
    Germania
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Belgio
  • —
    Non verificato
    Grecia

Domande comuni

What is iTTP?

iTTP is a rare blood disorder where your immune system mistakenly attacks healthy cells, causing tiny blood clots to form and leading to problems with your blood and organs.

What is plasma exchange?

Plasma exchange is a procedure that cleans your blood by removing harmful substances, often used to treat iTTP. This study is looking at ways to avoid needing it.

What is Cablivi?

Cablivi is a medicine being tested in this study. It's given as an injection and aims to stop the blood clots from forming in iTTP.

Will I still get other treatments if I join?

Yes, you would receive Cablivi along with other standard treatments that help calm your immune system.

Quanto durerà questo studio per me?

The main treatment phase will be about 12 weeks, followed by a monitoring period, making the total study time up to 24 weeks.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "An open-label, single-arm, multicenter study to evaluate the…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.